Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.

Park I, Cho YM, Lee JL, Ahn JH, Lee DH, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2013 May;139(5):817-27. doi: 10.1007/s00432-013-1386-4. Epub 2013 Feb 9. Erratum in: J Cancer Res Clin Oncol. 2013 Oct;139(10):1777-9.

PMID:
23397357
2.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

3.

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG.

J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

PMID:
17868729
4.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI.

J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.

PMID:
19064974
5.

Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.

Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS.

BJU Int. 2012 Jun;109(11):1600-6. doi: 10.1111/j.1464-410X.2011.10785.x. Epub 2012 Jan 5.

6.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK.

Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.

PMID:
24931622
7.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578. Epub 2014 Jan 23.

8.

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH.

J Surg Oncol. 2007 Mar 15;95(4):317-23.

PMID:
17066434
9.

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.

Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S.

Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4.

PMID:
25472645
10.

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A.

J Clin Oncol. 1999 Feb;17(2):523-8.

PMID:
10080595
11.

Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.

Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

Urol Oncol. 2015 Oct;33(10):427.e17-23. doi: 10.1016/j.urolonc.2015.04.011. Epub 2015 May 23.

12.

Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.

Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar M, Porfiri E.

Clin Genitourin Cancer. 2014 Aug;12(4):251-5. doi: 10.1016/j.clgc.2013.12.001. Epub 2013 Dec 27.

PMID:
24560086
13.

Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.

Bex A, Haanen JB, Vyth-Dreese FA, Horenblas S, de Gast GC.

Urol Int. 2008;80(4):367-71. doi: 10.1159/000132693. Epub 2008 Jun 27.

PMID:
18587246
14.

A novel prognostic model for patients with sarcomatoid renal cell carcinoma.

Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA.

BJU Int. 2015 Mar;115(3):405-11. doi: 10.1111/bju.12781. Epub 2014 Oct 19.

15.

Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.

Park JY, Lee JL, Baek S, Eo SH, Go H, Ro JY, Cho YM.

Hum Pathol. 2014 Jul;45(7):1437-44. doi: 10.1016/j.humpath.2014.02.019. Epub 2014 Mar 6.

PMID:
24784922
16.

Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.

You D, Jeong IG, Song C, Lee JL, Hong B, Hong JH, Ahn H, Kim CS.

Jpn J Clin Oncol. 2015 Jan;45(1):96-102. doi: 10.1093/jjco/hyu171. Epub 2014 Oct 23.

PMID:
25341544
17.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

18.

Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.

Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB.

Abdom Radiol (NY). 2016 Feb;41(2):295-302. doi: 10.1007/s00261-015-0569-7.

PMID:
26867911
19.

Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.

Kim SH, Kim JK, Park B, Joo J, Joung JY, Seo HK, Lee KH, Chung J.

Oncotarget. 2017 Jul 25;8(30):49615-49624. doi: 10.18632/oncotarget.17865.

20.

Supplemental Content

Support Center